Abstract:Heat shock protein 90 (HSP90) has emerged as an important target in cancer treatment because many of its clients are crucial in malignant transformation. HSP90 inhibitors such as antibiotic anismycin Geldanamycin and its derivatives 17-AAG promote degradation of client proteins. Several preclinical observations have made HSP90 inhibitors attractive drugs to the treatment of cancer. First, HSP90 inhibitors may provide a broader and effective anticancer therapy. Second, HSP90 in tumor cells was shown to exhibit much higher affinity for its inhibitors. HSP90 inhibitors such as 17-AAG and 17-DMAG are currently used targeting a variety of tumors in clinical trials. The TGFβ signaling pathway represents a major tumor suppressor pathway in normal epithelial cells, and paradoxically, it also acts as a significant promoter of tumor progression, invasion and metastasis in carcinomas. Since tumors are often detected in late stages, inhibition of TGFβ signaling pathway may be beneficiary to cancer patients. Several attempts in the past several years have highlighted the potential of blocking TGFβ responses in tumors by using soluble TGFβ receptors or competitive small molecules targeting the TGFβ receptors in anti-cancer therapy. Notably, the toxicity of TGFβ inhibition is well tolerated in mouse models, suggesting the strong potential of anti-TGFβ therapeutics in cancer. Our recent identification that TGFβ receptors are client proteins of HSP90 provides novel insights into the potential of HSP90 inhibitors in anti-cancer therapies. Objective: (1) To elucidate the molecular mechanisms underlying essential role of HSP90 in controlling TGFβ signaling in normal and cancer cells; (2) To explore the potential of HSP90 inhibitors as anti-metastasis therapeutics in breast cancer. Methods: Using a proteomic approach, we found an association between HSP90 and TGFβ receptors (both TβRI and TβRII). Further TβR-HSP90 interaction, TβR turnover and Smad2 phosphorylation were carried out using immunoprecipitation and western blotting. Dosage and duration of treatment with HSP90 inhibitors GA, 17-AAG, and Ridicicol were initially established by evaluating the blockade of TGFβ-induced Smad2 phosphorylation. Effect of HSP90 inhibitors and HSP90 siRNAs on the expression of TGFβ target gene transcription will be assessed by real-time RT-PCR. Cell proliferation was assayed by 3H-thymidine incorporation, and cell invasiveness was done in BD Matrigel Invasion Chambers in MDA-MB-231 breast carcinoma cells. Results: Using biochemical assays, we confirmed that TGFβ receptors (both TβRI and TβRII) physically associated with HSP90 proteins in a variety of normal and cancer cells. We next found that inhibition of HSP90 functions by several HSP90 inhibitors can promote the rapid turnover of TGFβ receptors in a ubiquitination/proteasome-dependent manner. Consequently, HSP90 inhibitors inhibit TGFβ-mediated phosphorylation of tumor suppressors SMAD2 and SMAD3, and block TGFβ-dependent transcription of genes such as MMP9. At the cellular level, HSP90 inhibitors led to the blockade of TGFβ-induced invasiveness of MDA-MB-231 breast carcinoma cells. Conclusion: We have identified HSP90 inhibitors as potential drugs blocking TGFβ functions. This study should help to understand the mechanisms of TGFβ and HSP90 interplay in progression of human cancers. Our study will also provide invaluable information on the use of HSP90 inhibitors for the treatment of human cancers.

Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors

Curcumin Enhances Bortezomib Treatment of Myeloma by Inhibiting Heat Shock Protein 90 Expression

A truncation in the aryl hydrocarbon receptor of the CRL:WI(Han) rat does not affect the developmental toxicity of TCDD.

Involvement of IgG Derived from Cancer in Tumor Immune Escape (P2147)

Immunomodulatory Effects of Intravenous Immunoglobulins as a Treatment for Autoimmune Diseases, Cancer, and Recurrent Pregnancy Loss

Intravenous immunoglobulin is safe and effective in controlling pre-existing paraneoplastic neuromuscular diseases in cancer patients treated with immune checkpoint inhibitors: two case reports and literature review

Effect of glioma-derived immunoglobulin on biological function of glioma cells

QS288. Potent Blockade of TGF-β Signaling by HSP90 Inhibitors

High-Dose Weekly Intravenous Immunoglobulin to Prevent Infections in Patients Undergoing Autologous Bone Marrow Transplantation or Severe Myelosuppressive Therapy: A Study of the American Bone Marrow Transplant Group

Sterically stabilized liposomes. Reduction in electrophoretic mobility but not electrostatic surface potential.

Therapeutic Efficacy of High-Dose Intravenous Immunoglobulin Inmycobacterium Tuberculosisinfection in Mice

Neuroprotective Effect of Polyvalent Immunoglobulins on Mouse Models of Chemotherapy-Induced Peripheral Neuropathy

Quantitative in vivo assessment of radiation injury of the liver using Gd-EOB-DTPA enhanced MRI: tolerance dose of small liver volumes

The relevance of tumor target expression levels on IgA-mediated cytotoxicity in cancer immunotherapy

Fc Gamma Riii-Dependent Inhibition Of Interferon-Gamma Responses Mediates Suppressive Effects Of Intravenous Immune Globulin

HSP90 inhibition acts synergistically with heat to induce a pro-immunogenic form of cell death in colon cancer cells

Cancer-IgG Upregulation of Radioresistance in Non-Small Cell Lung Cancer Patients and Cell Lines.

Massive immune response against IVIg interferes with response against other antigens in mice: A new mode of action?

Abstract 4606: Heat shock proteins in immunosuppressive tumor microenvironment

Effect of immunoglobulins secreted by murine myeloma cells on their own proliferation

Thymoglobulin targets multiple plasma cell antigens and has in vitro and in vivo activity in multiple myeloma